Introduction {#Sec1}
============

*Escherichia coli* has been accepted as both a biological indicator of water contamination and a human pathogen implicated in both systemic (e.g. septicemia, urinary tract infection, meningitis, etc) and superficial infections (skin or wound infection) \[[@CR1]--[@CR6]\]. *E. coli* is part of the normal flora of the gastrointestinal tract, shed along with faecal waste also including release by infected and convalescent individuals through poorly managed wastewater \[[@CR7], [@CR8]\]. The public health impact of the *E. coli* released depends partly on the antibiotic susceptibility pattern of the organism, as this determines the clinical treatment option(s) available \[[@CR9]\]. In specific terms, Park \[[@CR10]\] inferred that resistance to third-generation cephalosporin and carbapenem by Gram-negative bacteria in the community is very difficult to manage. In South Africa, cefotaxime is extensively in use \[[@CR11]--[@CR13]\], as supported by Section 21 of South African constitution \[[@CR11]\]. Koopmans et al. \[[@CR12]\] reported that cefotaxime is one of the two most used antibiotics in pediatric ward and pediatric intensive care unit of South African hospitals.

On the global level, the resistance of *E. coli* (and other members of the Enterobacteriaceae) to cefotaxime has been categorized to be of a critical threat to the public health by the World Health Organization, WHO \[[@CR14]\], for which research is seriously required. The threat associated with the resistance to these groups of antibiotics is due to their use as last line of defense against infections. Bacterial species showing resistance to them usually possess both genes and enzymes capable of conferring resistance to other antibiotics \[[@CR15], [@CR16]\].

Resistance to cefotaxime (cephalosporin) is often due to production of enzymes like extended-spectrum beta-lactamases, ESBLs encoded by the beta-lactamase genes, such as *bla*~*CTX-M*~ \[[@CR16]--[@CR19]\]. The same bacterial species containing the *bla*~*CTX-M*~ may also contain *bla*~*TEM*~ and/or *bla*~*SHV*~, especially among clinical isolates \[[@CR20], [@CR21]\]. If found in municipal wastewater, they might be an indication of clinical origin \[[@CR21]\] and also important, because wastewater treatment plants (WWTPs) are hotspots for antibiotic-resistant bacteria or resistance genes and it can be used as early warning signs on the health of the human population. Diwan et al. \[[@CR22]\] showed the detection of 88% *bla*~*CTX-M*~ gene bearing *Enterobacteriaceae* isolates while Korzeniewska and Harnisz \[[@CR18]\] reported that 55% of the same types of bacterial strain harbored the gene*.* D'Andrea et al. \[[@CR19]\] reported *bla*~*CTX-M*~ as the primary basis of resistance to the third-generation cephalosporins in *E. coli* isolated from clinical and environmental samples. In Nicaragua, *bla*~*CTX*-M~ genes were detected among ESBL-producing *E. coli* from hospital wastewater samples \[[@CR17]\].

For cefotaxime resistant *E. coli* with these ESBLs genes, their threat becomes more critical if they also possess carbapenem resistance genes, *bla*~*VIM*~*, bla*~*OXA-1*~*, bla*~*KPC-2*~*, bla*~*NDM-1*~, etc. \[[@CR23]\]. Carbapenem resistance genes code for resistance against imipenem, meropenem, ertapenem, doripenem etc. *E. coli* with carbapenem resistance and carbapenem resistance genes in the treated hospital effluent possesses potential epidemiological threat globally, as the bacteria may initiate difficult to treat infection among the exposed groups \[[@CR24]--[@CR27]\]. Transfer of antibiotic resistance genes can also be interspecifically and intraspecifically, given a suitable environment \[[@CR27]\]. Most beta-lactamase genes are plasmid based and can easily be transferred in biofilm formed within wastewater systems or in lakes \[[@CR28], [@CR29]\]. Exchange of plasmids and other mobile genetic elements containing beta-lactamase genes does occur in water, which serves as cushioning matrix in the process \[[@CR30]\]. *E. coli* and other bacteria originating from different sources interact within the wastewater matrix and may modify bacterial ecosystems therein \[[@CR31]\], depending on the duration of the interaction. Though WWTPs are to reduce the biological contamination of water, the efficiency of treatment would determine the potential release of bacteria with a critical epidemiological threat like cefotaxime resistant *E. coli*.

Some reports inferred that the conditions in WWTPs give room for the interaction of antibiotic-resistant bacteria and the exchange of mobile genetic elements \[[@CR30]--[@CR32]\]. Surveillance of the release of these WWTPs is imperative, to determine the biological status like the presence of cefotaxime resistant *E. coli* in the effluent that could constitute a threat. The aim of this study, therefore, was to assess and enumerate the cefotaxime resistant *E. coli* in influent and effluent samples of a wastewater treatment plant in Durban, South Africa and the corresponding sensitivity pattern to other selected antibiotics, as well as the presence of ESBL genes and other selected beta-lactamase genes in them.

Materials and methods {#Sec2}
=====================

Description of the sampling sites and sample collection {#Sec3}
-------------------------------------------------------

The sampling was done in a WWTP, treating municipal wastewater from Durban, Kwazulu Natal Province, South Africa in February (summer) and August (winter), 2017. The WWTP receives inflow in the range of 12,000--14,000 m^3^ containing industrial, municipal and hospital inflow. The total influent Chemical Oxygen Demand (COD) was 250--1100 mg/L and the total effluent COD was 75 mg/L. Other WWTP information are tabulated in Table [1](#Tab1){ref-type="table"}. The treatment plant contained four primary settling tanks, six trickling filters, six settling tanks and three anaerobic digesters (unheated and unmixed). The plant was designed to provide service for 30,000 people (design capacity = 18.80ML/d; working capacity = 10.98 ML/d mixed). It contained a chlorination step for water disinfection before release to the recipient. Table 1Wastewater parameters from the WWTPWastewater parametersInfluent (mg/L)Effluent (mg/L)COD (total)250--110075Total-N10--600--25NH~4~-N10--600--25Total-P20--800--10NO~3~-N (Effluent)N/A0--10Suspended solids (Effluent)N/A25 μS/cmN/A means Not Available

In five sampling rounds representing different seasons both pre-grated influent and final (post-chlorinated) effluent samples were collected. The rationale for collecting pre-grated samples was to have the samples in the exact forms it entered the WWTP. To have the samples in the form in which the effluents released to the recipient water, post-chlorinated final effluent samples were collected. The samples transported in a cold chain analyzed within 12 h of collection.

Quantification and isolation of total *E. coli*, cefotaxime resistant *E. coli*, other coliforms and cefotaxime resistant coliforms {#Sec4}
-----------------------------------------------------------------------------------------------------------------------------------

Quantification of the bacteria was done using standard membrane filtration. Membrane Fecal Coliform (mFC) agar (500 g; Difco ref. 267,720) purchased from Quantum Biotech, South Africa was used as the medium for quantification. The media was prepared with 1% rosolic acid (Difco; ref. 232,281) purchased from Hach International. Ten-fold serial dilutions representative for the influent and effluent ranges of concentration were prepared using sterilized saline solution (0.85% (w/v) NaCl). The prepared samples were filtered through 0.2 μm cellulose acetate filters (Lasec, South Africa) in triplicates. The filters were placed on the mFC agar plates supplemented with 4 mg/L or 8 mg/L cefotaxime antibiotic (100 mg Cefotaxime sodium salt; Sigma; ref. C7039) and on agar plates without antibiotic supplements in line with UNESCO regulations for another ongoing project in our laboratory. Though 4 mg/L was optimized to be adequate for satisfactory results, continuation of both 4 mg/L and 8 mg/L throughout was to see potential variance over a while.

The resulting culture was incubated at 37 °C for 24 h. Enumeration of the total number of colonies depended on observation of specific colonial colorations (grey, pink and blue). *E. coli* forms blue colonies. Grey and/or pink colonies might not be coliforms. The selectivity of the media was determined by estimating the ratio of blue and total colonies.

Species-specific identification of *E. coli* {#Sec5}
--------------------------------------------

### Extraction of DNA {#Sec6}

Isolation of the DNA was done by the boiling method using the protocols of Salehi et al. \[[@CR33]\]. The young presumptive *E. coli* colonies of ≤24 h were suspended in 200 μL aliquots of distilled water. The suspension containing the isolates was mixed by vortexing until a mixture with thoroughly dissipated isolates formed. This was boiled at 95 °C for 15 min and subsequently centrifuged at 15000 rpm; at 4 °C for 15 min where after, the supernatant was removed and stored at − 20 °C for further assays.

### PCR based species-specific identification of *E. coli* {#Sec7}

PCR based species-specific identification of *E. coli* was done using the primers (Inqaba Biotechnical Industries, South Africa) specific for a conserved region of *E. coli* alanine racemase (*alr*) gene specified in Table [2](#Tab2){ref-type="table"} \[[@CR34], [@CR35]\]. The reaction mixture contained 12.5 μL of one taq quick load 2x master mix with standard buffer (Inqaba Biotechnical Industries, South Africa), 20 μM each of the forward and reverse primers, water and 3 μL of DNA template suspension in a final volume of 25 μL. Table 2Primer sequences and amplicon size of PCR-amplified gene targetsTarget speciesGene targetPrimer sequence 5′--3′Amplicon size (bp)*E. coliAlr*CTGGAAGAGGCTAGCCTGGACGAG366AAAATCGGCACCGGTGGAGCGATC

The cycling conditions for the PCR reaction started with an initial 6 min denaturation step at 95 °C, followed by 35 cycles containing denaturation at 95 °C for 20s, primer annealing/extension at 72 °C for 1 min 30 s, and a final extension for 5 min at 72 °C. *E. coli* WG5 was used as a positive control.

Agarose gel electrophoresis was performed at 80 V for 45 min in 2% agarose gel in Tris Acetate-EDTA (TAE) buffer, stained with Sybr Safe DNA gel stain (ThermoFisher Scientific, South Africa).

Antibiotic susceptibility testing (AST) in cefotaxime-resistant *E. coli* {#Sec8}
-------------------------------------------------------------------------

Phenotypic antibiotic susceptibility pattern of the selected and identified cefotaxime-resistant *E. coli* was performed following standards described by Cheesebrough \[[@CR36]\] and Clinical and Laboratory Standards Institute (CLSI) (CLSI M100--2017) \[[@CR37]\]. Fifty-one (51) out of 75 selected isolates were subjected to first-round antibiogram. This was with the selection of 36 and 48 isolates for both colistin and gentamicin, respectively, based on the results from the first series of antibiotics tested. The antibiotics used included meropenem (10 μg), colistin (10 μg), amoxicillin-clavulanic (30 μg), ciprofloxacin (5 μg), trimethoprim-sulphamethoxazole (1.25/23.75 μg), gentamicin (10 μg), tetracycline (30 μg) and nitrofurantoin (300 μg).

### Multiple antibiotic resistance (MAR) index of cefotaxime-resistant *E. coli* to other antibiotics {#Sec9}

Multiple antibiotic resistance index (MAR Index) was determined per isolate as the ratio of the number of antibiotics to which an isolate showed resistance (X) to the total number of antibiotics against which the isolate was tested (Y) \[[@CR38]--[@CR40]\]. $$\documentclass[12pt]{minimal}
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This was determined on all the isolates concerning all the antibiotics used.

Detection of genes for extended spectrum beta-lactamases and carbapenemases in cefotaxime-resistant *E. coli* {#Sec10}
-------------------------------------------------------------------------------------------------------------

### Multiplex PCR for bla~CTX~, bla~TEM~ and bla~SHV~ {#Sec11}

Multiplex PCR assay was carried out to detect *bla*~*CTX*~*, bla*~*TEM*~ and *bla*~*SHV*~ (Table [3](#Tab3){ref-type="table"}). The PCR reaction mixture of 25 μL contained 12.5 μL of one taq quick load 2x master mix with standard buffer (Inqaba Biotechnical Industries, South Africa), 20 μM each of the forward and reverse primers, water and 3 μL of DNA template suspension. The cycling conditions for the PCR assay included an initial denaturation at 95 °C for 5 min, 30 cycles at 95 °C for 30 s and 68 °C for 40 s and a final extension at 68 °C for 3 min. Table 3Primer sequences, genes for beta-lactamase and the expected amplicon sizesGroupGene namePrimer sequence (5′--3′)Expected amplicon size (bp)ESBLS genes***bla***~***TEM***~GTCGCCGCATACACTATTCTCA258CGCTCGTCGTTTGGTATGG***bla***~***CTX*-*M***~CGGGAGGCAGACTGGGTGT381TCGGCTCGGTACGGTCGA***bla***~***SHV***~GCCTTGACCGCTGGGAAAC319GGCGTATCCCGCAGATAAATCarbapenemase genes***bla***~***VIM***~GATGGTGTTTGGTCGCATA390CGAATGCGCAGC***bla***~***OXA-1***~TTCTGTTGTTTGGGTTTCGC190ACGCAGGAATTGAATTTGTTC***bla***~***KPC*-*2***~GCTTCCCACTGTGCAGCTCATTC213CGCCCAACTCCTCAGCAACAATTG***bla***~***NDM-1***~GGTGCATGCCCGGTGAAATC660ATGCTGGCCTTGGGGAACG

Agarose gel electrophoresis also performed in 2% agarose gel in Tris Acetate-EDTA (TAE) buffer, stained with Sybr Safe DNA gel stain (ThermoFisher Scientific, South Africa).

### Singleplex PCR for the detection of *bla*~*VIM*~*, bla*~*OXA-1*~*, bla*~*KPC-2*~*, bla*~*NDM-1*~ {#Sec12}

Singleplex PCR was performed for the detection of *bla*~*VIM*~*, bla*~*OXA-1*~*, bla*~*KPC-2*~*, bla*~*NDM-1*~ using the primers listed in Table [3](#Tab3){ref-type="table"}. For *bla*~*VIM*~*,* the cycling conditions included the initial denaturation at 94 °C for 3 min, followed by a stage of 36 cycles containing denaturation at 94 °C for 1 min, annealing at 55 °C for 1 min, extension at 72 °C for 1 min and a final extension at 72 °C for 5 min. PCR cycling conditions for *bla*~*OXA-1*~ began with initial denaturation at 95 °C for 2 min, followed by a stage of 30 cycles containing denaturation at 94 °C for 45 s, annealing at 55 °C for 30 s and extension at 72 °C at 1 min. This was followed by a final extension stage at 72 °C for 5 min.

The detection of *bla*~*KPC-2*~ was done with cycling conditions that included an initial denaturation at 95 °C for 5 min, followed by a stage of 40 cycles containing denaturation at 95 °C for 15 s, annealing at 66.1 °C for 30 S, extension at 72 °C for the 30 S and final extension at 72 °C for 10 min \[[@CR41]\]. For *bla*~*NDM-1*~, the cycling conditions began with denaturation at 95 °C for 15 min, followed by a stage of 30 cycles containing 95 °C for 1 min denaturation, 61.1 °C for 1 min annealing, and extension for the 30 S at 72 °C. This was followed by a final extension for 10 min at 72 °C \[[@CR42]\].

### Pathotyping of the *E. coli* {#Sec13}

Isolated and identified *E. coli* were further pathotyped to determine which strains they were, using the primers listed in Table [4](#Tab4){ref-type="table"}. For molecular characterization of *E. coli* pathotypes, the thermal cycling conditions for Enteroaggregative *E. coli* (EAEC), Enteropathogenic *E. coli* (EPEC) and Enterotoxigenic *E. coli* (ETEC) (Heat Labile, LT) were as follows: the initial denaturation/enzyme activation step at 95 °C for 15 min, followed by 35 cycle consisting of denaturing at 94 °C for 45 s, annealing at 55 °C for 45 s, extension at 68 °C for 2 min and the final elongation at 72 °C for 5 min \[[@CR43]\]. The cycling conditions for EIEC were: 96 °C for 4 min; 35 cycle of 94 °C for 30 s, 58 °C for 30 s and 72 °C for 1 min; and a final 7 min extension at 72 °C \[[@CR44]\] while those for ETEC (Heat Stable, ST) were as follows: 95 °C for 5 min, followed by 30 cycles of 95 °C for 1 min, 60 °C for 1 min, 72 °C for 1 min, and 72 °C for 10 min final extension \[[@CR45]\]. Table 4Primer sequences and expected amplicon sizes of the pathogenic Strains of *E. coli* (Pathotyping)Target strainGene TargetPrimer Sequence (5′--3′)Amplicon Size (bp)EAEC*Eagg*AGA CTC TGG CGA AAG ACT GTA TC194ATG GCT GTC TGT AAT AGA TGA GAA CEPEC*EaeA*CTG AAC GGC GAT TAC GCG AA917GAC GAT ACG ATC CAGETEC*LT*GGC GAC AGA TTA TAC CGT GC450CGG TCT CTA TAT TCC CTG TT*ST*ATTTTTCTTTCTGTATTGTCTT190CACCCGGTACAAGCAGGATTEIEC*shig*CTGGTAGGTATGGTGAGG320CCAGGCCAACAATTATTTCC

Statistical analysis {#Sec14}
--------------------

Statistical analysis was performed for descriptive statistics. Plating of the samples was done in triplicates. The values were plotted using Box and Whiskers, Microsoft Office Excel 2016 (Microsoft, Redmond, WA, USA) which automatically calculated and depicted the standard deviations (SDs) and the spread of data. Differences in antibiotic resistance between ESBL positive *E. coli* and carbapenemase positive *E. coli* were determined using the chi-square test at *p* value \< 0.05 (significant). The test of significance for seasonal variation (*p* \< 0.05) was done using GraphPad software, version 5.01.

Results {#Sec15}
=======

Quantification of total *E. coli* and cefotaxime-resistant *E. coli* {#Sec16}
--------------------------------------------------------------------

Large counts of cefotaxime-resistant *E. coli* were resident in the wastewater. A very high mean total *E. coli* count of over 6 log~10~ CFU/mL was found in the influent sample (represented with Inf SR-3 NA in Fig. [1](#Fig1){ref-type="fig"}). Varying concentrations of cefotaxime-resistant *E. coli* occurred with differences between the two concentrations of the antibiotic supplemented in the laboratory cultivation media. Higher numbers of resistant isolates were enumerated at cefotaxime concentration of 4 mg/L than at 8 mg/L as assumed, though this was inconsistent at one sampling occasion. Higher concentration of cefotaxime (8 mg/L) did not show reduction in the cefotaxime resistant *E. coli* counts beyond what lower concentration showed in a slight variation. Fig. 1**a** Count \[Log~10~ (CFU/mL)\] of Presumptive Total *E. coli* (TEc) and Cefotaxime Resistant *E. coli* (CREc) in summer Influent samples (**b**) Count \[Log~10~ (CFU/mL)\] of other Coliforms and Cefotaxime Resistant Coliforms in summer influent samples. Legend: Inf SR-3 NA = influent sample at sampling occasion 3 without antibiotic, Inf SR-3 A4 = influent sample at sample occasion 3 with 4 mg/L of cefotaxime antibiotic, Inf SR-3 A8 = influent sample 3 with 8 mg/L of cefotaxime antibiotic; Inf SR-2 NA = influent sample at sampling occasion 2 without antibiotic; Inf SR-2 A4 = influent sample at sample occasion 2 with 4 mg/L of cefotaxime antibiotic; Inf SR-2 A8 = influent sample 2 with 8 mg/L of cefotaxime antibiotic; Inf SR-1 NA = influent sample at sampling occasion 1 without antibiotic; Inf SR-1 A4 = influent sample at sample occasion 1 with 4 mg/L of cefotaxime antibiotic; Inf SR-1 A8 = influent sample 1 with 8 mg/L of cefotaxime antibiotic. Figure 1: **c** Count \[Log~10~ (CFU/mL)\] of Presumptive Total *E. coli* (TEc) and Cefotaxime Resistant *E. coli* (CREc) in Winter Influent samples (**d**) Count \[Log~10~ (CFU/mL)\] of other Coliforms and Cefotaxime Resistant Coliforms in Winter Influent samples. **e** Count \[Log~10~ (CFU/mL)\] of *E. coli* and other coliforms in effluent samples. Legend: Inf SR-4 NA = influent sample at sampling occasion 4 without antibiotic, Inf SR-4 A4 = influent sample at sample occasion 4 with 4 mg/L of cefotaxime antibiotic; Inf SR-4A8 = influent sample during sample occasion 4 with 8 mg/L of cefotaxime antibiotic; Inf SR-4 NA = influent sample at sampling occasion 4 without antibiotic; Inf SR-5 A4 = influent sample at sample occasion 5 with 4 mg/L of cefotaxime antibiotic; Inf SR-5 A8 = influent sample during sample occasion 5 with 8 mg/L of cefotaxime antibiotic; Eff SR-1 NA = effluent sample occasion 1 for *E. coli* without antibiotic supplementation; Eff SR-2 NA = effluent sample occasion 2 for *E. coli* without antibiotic supplementation; Eff SR-3 NA = effluent sample occasion 3 for *E. coli* without antibiotic supplementation; Eff SR-1 O-NA = effluent sample occasion 1 for other coliforms without antibiotic supplementation etc.

An approximate total *E. coli* count (log~10~ CFU/mL) ranged from 5.7 to 6.8, with cefotaxime resistant *E. coli* count (log~10~ CFU/mL) ranging between 1.8 to 4.9 for cefotaxime concentration of 4 mg/L and 2.3 to 2.8 at 8 mg/L. The influent counts (log~10~ CFU/mL) for the total *E. coli* count (NA) as well as cefotaxime-resistant *E. coli* (A4 and A8) for all the summer samples (SR-1, SR-2, SR-3) are presented in Fig. [1](#Fig1){ref-type="fig"}(a). The results of the other coliforms for summer as depicted in Fig. [1](#Fig1){ref-type="fig"}(b) contained a total count (log~10~ CFU/mL) that ranged from about 6.4 to 6.6, with one wide outlier of count 0, plotted separately from the range 6.4--6.6. The cefotaxime (4 mg/L) resistant coliforms counts (log~10~ CFU/mL) ranged from 0 to 4.7 while those for 8 mg/L ranged from about 2.6 to 2.9, presented in Fig. [1](#Fig1){ref-type="fig"}(b).

Seasonal variation was not significant (*p* \< 0.05) with an approximate total *E. coli* count (log~10~ CFU/mL) in winter that ranged from 5.2 to 6.6, cefotaxime-resistant *E. coli* count (log~10~ CFU/mL) ranged from 2.5 to 4.8 at concentration of 4 mg/L and 1.0 to 5.2 at concentration of 8 mg/L. The trend was also similar for other coliforms with a total count (log~10~ CFU/mL) that ranged from about 4.7 to 6.3; cefotaxime (4 mg/L) resistant coliforms counts (log~10~ CFU/mL) ranged from 2.3 to 3.5 and cefotaxime (8 mg/L) resistant coliforms counts (log~10~ CFU/mL) ranged from 0 to 2.9. The winter counts of *E. coli* and the other coliforms are represented in Fig. [1](#Fig1){ref-type="fig"}(c) and (d), respectively.

Meanwhile, there was consistently no total and cefotaxime-resistant *E. coli* growth and rarely very low growth (range in log~10~ CFU/mL = 0 to 0.3) in the effluent concentration (Fig. [1](#Fig1){ref-type="fig"}e). Therefore, the reduction efficiencies for total *E. coli* were in the range from 95.6 to 100%, while those estimated for cefotaxime-resistant were between 99 to 100%. Total coliforms in the effluent samples (without cefotaxime) however showed some appreciable counts (log~10~ CFU/mL) that ranged from 0 to 3.6 as in Fig. [1](#Fig1){ref-type="fig"}(e). Their removal efficiencies inconsistently ranged from 45.5 to 100%. The majority of the coliforms were sensitive to cefotaxime and did not grow on cefotaxime plates. There were more effluent samples without *E. coli* and coliform growth. Almost all the cefotaxime-supplemented plates for effluent showed no growth. The count of 1 CFU/mL in very few cases was estimated as 0 log~10.~

Antibiogram of cefotaxime-resistant *E. coli* {#Sec17}
---------------------------------------------

The results of the antibiotic susceptibility testing from cefotaxime resistant *E. coli* to additional antibiotics is presented in Table [5](#Tab5){ref-type="table"} together with percentage intermediates and susceptible isolates. Cefotaxime resistant *E. coli* also showed 35.3% resistance to amoxicillin-clavulanic acid, 76.5% to colistin sulphate, 47.1% to ciprofloxacin, and 87.5% to Gentamicin. Table 5Susceptibility profile of cefotaxime resistant *E. coli* to other selected antibioticsAntibioticsPercentage of isolatesRISAmoxicillin-clavulanic acid35.352.911.8^a^Colistin sulphate76.511.85.9Meropenem011.888.2Ciprofloxacin47.123.529.4Trimethoprim-sulphamethoxazole81.3018.8^b^Gentamicin87.512.50Tetracycline56.3037.5Nitrofurantoin37.52537.5*R* Resistance, *I* Intermediate, *S* Sensitive, *n* = 51; ^a^*n* = 36; ^b^*n* = 48

Multiple antibiotic resistance index (MAR index) {#Sec18}
------------------------------------------------

A large percentage (\> 94%) of the *E. coli* isolates had a MAR index above 0.2. The corresponding figures were 41.2% with a MAR index of 0.5 and 29.4% with an index of 0.75 (See Fig. [2](#Fig2){ref-type="fig"}). Fig. 2MAR Index of the cefotaxime resistant *E. coli* and their percentage of isolates

Bata lactamase genes in cefotaxime-resistant *E. coli* {#Sec19}
------------------------------------------------------

The presence of various beta-lactamase genes among the cefotaxime-resistant *E. coli* occurred*.* For extended-spectrum beta-lactamase (ESBL) genes, *bla*~*CTX-M*~ was detected in 52.6% of the isolates and *bla*~*TEM*~ in 84.2%, while no *bla*~*SHV*~ was detected. Both *bla*~*CTX-M*~ and *bla*~*TEM*~ were concurrently detected among 36.8% of the *E. coli* isolate. Carbapenem resistance gene, *bla*~*KPC-2*~ was detected among 15.8% of the isolates, *bla*~*OXA-1*~ among 57.9% of the *E. coli* isolates, while *bla*~*NDM − 1*~ occurred in 15.8% of the *E. coli* isolates. No *bla*~*VIM*~ was detected. Carbapenem-resistance genes, *bla*~*KPC-2*~ and *bla*~*OXA-1*~ were found in 15.8% of the isolates. *bla*~*NDM-1*~ and *bla*~*OXA-1*~ were also concurrently detected in 10.5%. Both ESBLs genes and carbapenemase genes were concurrently detected in some isolates, with the highest being *bla*~*TEM*~ and *bla*~*OXA-1*~ simultaneously detected in 52.6% of the isolates. Fewer isolates showed the presence of the putative genes for carbapenemases than ESBLs. In addition, there was statistically significant difference (*p* \< 0.05) between most carbapenem-resistance genes (*bla*~*KPC-2,*~*bla*~*NDM-1,*~*bla*~*KPC-2\ +*~*bla*~*OXA-1*~ and *bla*~*NDM-1\ +*~*bla*~*OXA-1)*~ and ESBL genes (*bla*~*CTX-M*~ and *bla*~*TEM*~). The details of the beta-lactamase genes are displayed in Table [6](#Tab6){ref-type="table"}. Table 6Selected beta-lactamase genes in cefotaxime resistant *E. coli* from wastewater treatment plantsGroupBeta-lactamase genes%ESBLs genes (A)*n* = 38*blaCTX-M*52.6*blaTEM*84.2*blaSHV*0*blaCTX-M + blaTEM*36.8Carbapenem genes (B)*n* = 38*blaKPC-2*15.8*blaOXA-1*57.9*blaVIM*0*blaNDM-1*15.8*blaKPC-2 + blaOXA-1*15.8*blaNDM-1 + blaOXA-1*10.5A + B*n* = 38*blaCTX-M + blaKPC*10.5*blaCTX-M* + *blaOXA-1*36.8*blaCTX-M* + *blaNDM-1*10.5*blaTEM* + *blaKPC-2*15.8*blaTEM* + *blaOXA-1*52.6*blaTEM* + *blaNDM-1*15.8

Pathotypes of the isolates {#Sec20}
--------------------------

The results of the pathotyping showed that 70% (*n* = 30) of the selected isolates were confirmed as pathogenic; 7 (23.3%) were heat-stable (ST) enterotoxigenic *E. coli* (ETEC), 14 (46.7%) were Enteroaggregative *E. coli* (EAEC), but no enteropathogenic *E. coli* (EPEC) and enteroinvasive *E. coli* (EIEC) were detected. Figure [3](#Fig3){ref-type="fig"} showed the comparison of the various pathotypes. Fig. 3Pathotypes of selected cefotaxime resistant *E. coli* (*n* = 30)

Discussion {#Sec21}
==========

We conducted this study with the aim of quantifying the cefotaxime-resistant *E. coli* and determining antibiogram to other antibiotics, as well as the presence of beta-lactamase genes in the Gram-negative bacteria from a WWTP from Durban, South Africa. This aim is in line with the critical criteria placed on Enterobacteriaceae resistant to third-generation cephalosporin and carbapenem antibiotics by WHO \[[@CR14]\]. The distribution of resistant *E. coli* to the environment through wastewater effluents remains an issue of public health concern, depending on downstream human exposure. A large number of total *E. coli* count (log~10~ CFU/mL) that ranged from 5.7 to 6.8 or cefotaxime-resistant *E. coli* as depicted in Fig. [1](#Fig1){ref-type="fig"}(a) - (d) in the influent may not really be of much concern. The former (total *E. coli*) is expected in influent since *E. coli* is a normal part of the gut flora \[[@CR7], [@CR8]\]. The presence of the latter (cefotaxime-resistant *E. coli*) might also be due to wastewater from hospital inflow. These resistance attributes are expected from the clinical origin \[[@CR20], [@CR21], [@CR46]\] and since the WWTPs are known as early warning system \[[@CR47]\], the presence of a large number of cefotaxime-resistant *E. coli* might be a warning sign of probable lack of pretreatment for the hospital outflow.

The effluent concentration of both total *E. coli* and cefotaxime-resistant *E. coli* (range in log~10~ CFU/mL = 0 to 0.3) (Fig. [1](#Fig1){ref-type="fig"}e) was low and in most cases zero due to the chlorination practices. Even when the bacterial cells confirmed to be dead after chlorination, studies have shown that large percentage of their genes persists in the effluent \[[@CR48]\]. These genes can be picked up by competent environmental strains of *E. coli,* conferring the antibiotic resistance status of the dead organism on the new \[[@CR27]\]. These competent cells might accidentally be among other total coliforms with effluent concentration (log~10~ CFU/mL) that ranged from 0 to 3.6. This is possible because transformation only requires a competent cell to pick up resistance genes in the environment, even if the donor is from another genus \[[@CR27], [@CR49]\].

Though many cefotaxime-resistant Gram-negative bacteria are already recognized as critical threats \[[@CR11]\], their further resistance to other antibiotics within the last line of defense poses a greater threat toward total resistance \[[@CR50], [@CR51]\]. Gentamicin resistance (87.5%) detected in our study was in tandem with the reports by Jakobsen et al. \[[@CR52]\]. It was revealed that the isolates showed intermediate resistance to meropenem (11.8%) as well as resistance to ciprofloxacin (47.1%) and colistin sulphate (76.5%) by cefotaxime-resistant *E. coli*. Fluoroquinolone resistant isolates of *E. coli* from sewage had also been reported by Colomer-Lluch et al. \[[@CR53]\]. The corresponding threat is because fluoroquinolones (e.g. ciprofloxacin) ranked as one of four highest prioritized critically important antimicrobials \[[@CR54]\]. A figure of about every 1 in 2 (47.1%) as detected in this study for ciprofloxacin and cefotaxime-resistant *E. coli* is synonymous with having a 12.5% chance of therapeutic failure or total resistance, in line with the position of WHO \[[@CR50]\]. The colistin resistance (76.5%) in Enterobacteriae in this study is in worrying tandem with the report of 100% colistin resistance in lake water and 33.3% in sewage found by Fernandes et al. \[[@CR55]\]. Resistance to colistin by environmental or clinical isolates is significantly related to resistance to some other antibiotics in the last line of defense \[[@CR56]\]. Colistin administration induces an increase in carbapenemase-producing *Enterobacteriaceae* around the world and resistance to colistin itself is directly linked with the agricultural use of human antibiotics \[[@CR56]\]. The resistance of 35.3% to amoxicillin-clavulanic acid revealed that the basis of resistance in some of the isolates in this study goes beyond beta-lactamase production. This is because clavulanic acid would have inhibited the effect of the enzyme to ensure susceptibility to the antibiotic. This profile highlighted the bacteria as a potential threat for any less kitted workers in WWTPs due to the risks of occupational exposure \[[@CR57]\].

The discharge of the antibiotic-resistant bacteria from WWTPs to the environment is reported widely \[[@CR32], [@CR49], [@CR51], [@CR52], [@CR58]--[@CR60]\]. Concurrent resistance to multiple antibiotics is an issue of greater concern. A wide range of multiple antibiotic resistance indices (0.13--0.75) might be a reflection of wide disparity in the static-use and the adaptive-use of these antibiotics \[[@CR37]\]. This may signify a consistent administration of these antibiotics without medical prescription or the organisms originating from hospital environment \[[@CR60]\]. Large percentage (\> 94%) of the cefotaxime-resistant *E. coli* exhibited multiple antibiotic indices (MAR Index) \> 0.2 which means that the isolates might have originated from high risk source (s), where antibiotics are probably abused \[[@CR38], [@CR40], [@CR59]\]. As noted earlier, since the WWTPs are known as early warning systems \[[@CR47]\], the MAR Indices in this study revealed that antibiotics are in constant abuse and hence, their high selective pressure \[[@CR61]\].

The high resistance to colistin sulphate (76.5%) detected in this study is considered alarming. Over the past few years now, attention around the world has been especially focused on the epidemiology of resistance to colistin in bacteria. Researchers link the emergence of colistin resistance to prior exposure to the sublethal concentration by the bacteria, but studies have reported the isolation of colistin-resistant *E. coli* strains from individuals without history of colistin usage \[[@CR62]\]. In a study in Laos, Olaitan et al. \[[@CR63]\] isolated colistin-resistant *E. coli* from a boy without any record of prior administration of colistin but rather probable zoonotic exposure from the family's pigs. This is why animal or infected human feces like in waste and wastewater are considerable hotspots \[[@CR64], [@CR65]\]. Colistin is used as the final alternative for resistant isolates against β-lactams, aminoglycosides or quinolones, but colistin-resistant Enterobacteriaceae have been classified with pan-drug resistance \[[@CR66]\]. So, infections from the *E. coli* isolated from the sampled WWTP can be difficult to treat in an individual if contracted via occupational exposure.

Several antibiotic resistance determinants were detected in this study. These include *bla*~*TEM*~*, bla*~*CTX-M*~*, bla*~*SHV*~*, bla*~*VIM*~*, bla*~*OXA-1*~*, bla*~*KPC-2*~ and *bla*~*NDM-1*~, which might be responsible for some detected resistance to the cefotaxime and other beta-lactam antibiotics \[[@CR67]\]. Though *bla*~*VIM*~ was not detected, *bla*~*OXA-1*~*, bla*~*KPC-2*~ and *bla*~*NDM-1*~ might be responsible for intermediate resistance to meropenem by the cefotaxime-resistant *E. coli* \[[@CR67], [@CR68]\]. Several beta-lactamase genes like *bla*~*CTX-M*~*, bla*~*SHV*~ and *bla*~*TEM*~ have also been reported in both hospital and municipal wastewater effluents \[[@CR18], [@CR69]\]. These reports, as well as our report, indicate the possibility for the determinants to be disseminated among water systems \[[@CR70]\], since the genes may persist after the bacterial cells are dead \[[@CR48]\]. Concurrent detection of at least two ESBLs' genes, two carbapenem resistance genes and ESBLs with carbapenem resistance genes (Table [6](#Tab6){ref-type="table"}) depicted the level of threat associated with these bacterial strains.

Reports in other studies \[[@CR71], [@CR72]\] showed that ESBL producers from WWTP were *E. coli* and *K. pneumoniae*. Most rampant putative ESBLs' genes were *bla*~CTX-M~ genes in which the similar gene types were detected in both clinical and environmental isolates \[[@CR73], [@CR74]\]. Multi-drug resistant *E. coli* (MDR-*Ec*), have been isolated from a healthy human \[[@CR75]\] and the MDR-*Ec* is sometimes shed in feces released into WWTP through the user interface. Intraspecific and interspecific transfer of resistance gene was expected to be high in the WWTP due to high bacterial density. This transfer may include rampant *bla*~CTX-M~ (Coque et al., 2008).

Since 70% (*n* = 30) of the selected isolates were confirmed as pathogenic due to their pathotypes (Fig. [3](#Fig3){ref-type="fig"}), their release into the environment may pose threat to public health and to the environment, as these attributes may be widely distributed causing too difficult to control bacterial infection in an epidemic proportion.

Conclusions {#Sec22}
===========

The influent samples in the WWTP contained a large number of Cefotaxime-resistant *E. coli* and other coliforms but the effluent contained only a very scanty concentration of total *E. coli* and other coliforms. Some of the cefotaxime resistant *E. coli* also showed resistance to amoxicillin-clavulanic acid, colistin, meropenem, ciprofloxacin, gentamicin, trimethoprim-sulphamethoxazole, nitrofurantoin and tetracycline. The presence of cefotaxime-resistant and indeed multidrug-resistant Enterobacteriaceae in wastewater influent showed that these organisms, classified with critical threats, were possibly harbored in the population. These, cefotaxime-resistant *E. coli,* were pathogenic as revealed by their pathotypes. These resistant isolates bore extended-spectrum beta-lactamase genes and carbapenem resistance genes singly and concurrently, which make them of potential clinical origin. It is imperative for hospitals to pretreat their wastewater effluent to avoid the critical threat associated with these kinds of bacteria to public health, in case of leakage and human exposure.
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